GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.
Company profile
Ticker
GSK, GLAXF
Exchange
Website
CEO
Emma Walmsley
Employees
Incorporated
Location
Industry (SIC)
Former names
GLAXOSMITHKLINE PLC
SEC CIK
GSK stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 24
6-K
Statement: Zantac (Ranitidine) Litigation
24 May 24
6-K
Positive Phase III Asthma Results for Depemokimab
21 May 24
6-K
Director/pdmr Shareholding
20 May 24
6-K
Current Report
17 May 24
6-K
GSK Completes Sale of Shares In Haleon PLC
17 May 24
6-K
Director/pdmr Shareholding
14 May 24
6-K
Block Listing Interim Review
13 May 24
6-K
Result of Agm
8 May 24
6-K
Board Committee Change
8 May 24
Latest ownership filings
SC 13D/A
Nkarta, Inc.
28 Mar 24
SC 13G/A
DODGE & COX
13 Feb 24
SC 13D/A
23andMe Holding Co.
9 Feb 24
SC 13G/A
CureVac N.V.
6 Feb 24
SC 13G/A
Wave Life Sciences Ltd.
6 Feb 24
4
Wave Life Sciences Ltd.
30 Jan 24
SC 13D/A
Haleon plc
19 Jan 24
SC 13D/A
Haleon plc
10 Oct 23
SC 13D/A
Haleon plc
11 Sep 23
SC 13D/A
BICYCLE THERAPEUTICS plc
20 Jul 23
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
14.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 841 |
Opened positions | 201 |
Closed positions | 87 |
Increased positions | 253 |
Reduced positions | 237 |
13F shares | Current |
---|---|
Total value | 10.46 tn |
Total shares | 291.82 mm |
Total puts | 1.31 mm |
Total calls | 2.87 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Dodge & Cox | 68.86 mm | $2.95 tn |
FMR | 24.58 mm | $1.05 tn |
JTC Employer Solutions Trusteee | 21.14 mm | $909.06 mm |
Fisher Asset Management | 15.67 mm | $671.70 bn |
MS Morgan Stanley | 12.47 mm | $534.63 bn |
T. Rowe Price | 11.47 mm | $491.52 mm |
Holocene Advisors | 8.72 mm | $373.81 bn |
RY Royal Bank Of Canada | 8.15 mm | $349.28 bn |
STT State Street | 6.96 mm | $301.17 bn |
Mondrian Investment Partners | 5.51 mm | $236.25 bn |
News
Goldman Sachs Initiates Coverage On GSK with Neutral Rating, Announces Price Target of $47
30 May 24
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
27 May 24
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
24 May 24
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
22 May 24
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
21 May 24
Press releases
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
2 Jun 24
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
7 May 24
WuXi Biologics Reports Solid 2023 Annual Results
26 Mar 24
Thinking about trading options or stock in Advanced Micro Devices, Amazon.com, Intel, GSK, or Viking Therapeutics?
21 Mar 24
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
16 Mar 24